Vol. 6 No. 8 (2026): August
Reimbursement Reviews

Maralixibat (Livmarli)

decorative image of the issue cover

Published August 11, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Maralixibat (Livmarli), 19 mg/mL oral solution and 10 mg, 15 mg, 20 mg, and 30 mg tablets
  • Indication: Proposed: Treatment of cholestatic pruritus in patients aged 12 months or older with progressive familial intrahepatic cholestasis (PFIC).